🚨 JUST IN: $BFRI
FDA approves Biofrontera's Ameluz PDT for superficial basal cell carcinoma; launch expected Q4 2026–Q1 2027

#SEC #stocks #investing #BFRI #Regulatory
🔗 secwatch.observer

#BFRI Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

https://www.stocktitan.net/news/BFRI/biofrontera-announces-fda-approval-of-ameluz-red-light-pdt-for-the-4x012o55xgtd.html?utm_source=stocktitan-bluesky&utm_medium=social